(Reuters) - Moderna Inc confirmed on Tuesday it had agreed to supply its COVID-19 vaccine candidate, mRNA-1273, to the United Kingdom starting from the beginning of March, as long as it succeeds in gaining local regulatory approval.
The company’s statement did not disclose other terms of the agreement, including the number of doses it agreed to supply.
U.K. Health Minister Matt Hancock told a news conference on Monday that the deal would see the U.S. startup, one of two vaccine makers who have so far published positive data on final-stage trials, supply five million doses from next spring.
Moderna on Monday said mRNA-1273 was 94.5% effective in preventing COVID-19 based on interim data from its late-stage clinical trial.
Read more from the original article: